VITRAKVI Maintains Market Leadership Across the 7MM Amid Growing TRK Inhibitor Competition | DelveInsight
DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...
Jazz Pharmaceuticals (JAZZ) Gets a Buy from Jefferies
In a report released on March 14, Akash Tewari from Jefferies maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a ...
Council on Foreign Relations3d
American Pharmaceutical Companies Still Aren’t Paying Tax in the U.S.
K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.
Unveiling Pharma Market Potential: DelveInsight's Strategic Insights into the Rapidly Expanding MASH Landscape in Asia
DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the ...
Merck opens manufacturing facility in North Carolina amid Trump's tariff threats
Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S.
Merck Opens Vaccine Manufacturing Facility in North Carolina
Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, as the drugmaker seeks to boost its U.S ...
DelveInsight Business Research, LLP: TEPMETKO Continues to Strengthens its Position as a Leading METex14 Skipping NSCLC Therapy | DelveInsight
With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...
Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance Delveinsight
Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which wil ...
DelveInsight Business Research, LLP: VERZENIO's Market Potential Soars as Demand for CDK4/6 Inhibitors Grows | DelveInsight
As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...
Benzinga.com14d
Eli Lilly's Options Frenzy: What You Need to Know
Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 33 trades. If we consider the specifics of each ...